AIGH Capital Management’s Cellectar Biosciences CLRB Stock Holding History

AIGH Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-106,580	Closed	-$6.84M	–	40
2024 Q3	$6.84M	Buy	106,580 +5,374	+5%	+$354K	1.93%	12
2024 Q2	$6.86M	Buy	101,206 +7,709	+8%	+$740K	2.14%	12
2024 Q1	$11.2M	Buy	93,497 +29,656	+46%	+$3.21M	3.35%	6
2023 Q4	$5.31M	Buy	63,841 +41,257	+183%	+$3.07M	2.1%	19
2023 Q3	$1.79M	Sell	22,584 -4,523	-17%	-$266K	0.85%	33
2023 Q2	$1.59M	Sell	27,107 -3,956	-13%	-$190K	0.65%	33
2023 Q1	$1.34M	Hold	31,063	–	–	0.49%	41
2022 Q4	$1.59M	Buy	31,063 +25,249	+434%	+$1.51M	0.53%	37
2022 Q3	$586K	Sell	5,814 -309	-5%	-$44.4K	0.18%	41
2022 Q2	$1.63M	Hold	6,123	–	–	0.43%	30
2022 Q1	$1.26M	Buy	6,123 +3,134	+105%	+$549K	0.31%	35
2021 Q4	$596K	Buy	+2,989	New	+$720K	0.18%	46

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIGH Capital Management's CLRB Position: Q4 2024 in Review

AIGH Capital Management sold out of Cellectar Biosciences (CLRB) in Q4 2024, closing a stake of 106,580 shares — an estimated $6.84M sold.

AIGH Capital Management first reported a position in CLRB in Q4 2021 and held it in 12 quarters. The position peaked at $11.2M in Q1 2024. 30 funds tracked by Wall St. Rank hold CLRB as of Q4 2024.

AIGH Capital Management reported no remaining Cellectar Biosciences position as of Q4 2024 after selling out during the quarter.
AIGH Capital Management sold 106,580 Cellectar Biosciences shares in Q4 2024, an estimated $6.84M.
AIGH Capital Management first reported a position in Cellectar Biosciences in Q4 2021 and held it in 12 quarters.
AIGH Capital Management's Cellectar Biosciences position peaked at $11.2M in Q1 2024.
30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2024.

Based on AIGH Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.